[Absence of hypolipidemic effect of Solanum melongena L. (eggplant) on hyperlipidemic patients].
In this study we investigated the hypolipidemic potential of dried powdered fruits of eggplant (Solanum melongena), which has been commercialized in Brazil to treat human hyperlipidemia. Thus, a double-blind placebo-controlled study of the effectiveness of oral Solanum melongena (SM) was conducted. The study consisted of 41 hyperlipidemic volunteers allocated to active treatment (n= 21) or placebo (n= 20). Each volunteer received two capsules containing SM (450 mg) or placebo (450 mg) twice daily and were followed monthly. The dose of SM used corresponds to that given to treat hyperlipidemia in Brazil. After 3 months, serum total cholesterol, LDL-c and LDL-c/HDL-c decreased (p<0.05) in the group treated with SM. However similar effect was also observed in the placebo group. The other parameters, including serum triglycerides, HDL-c, VLDL-c, AST, ALT, gGT, glucose and body mass index, showed no significant changes. We conclude that SM, at least in the form commercialized in the Brazil (dried powdered fruits), require further clinical trials before being recommended to treat hyperlipidemia.